忘了密码 Forgot your password? 新用户登记 Create an account.
SCAPE 张玉蛟教授 5/13/2015 在世界权威杂志柳叶刀 Lancet 发表重大临床科研成果，SABR 在手术可切除早期肺癌取得比手朮治疗更好的疗效。
Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather than the current standard of care invasive surgery according to research from a phase III randomized international study. Estimated three-year survival rates were 79 percent in the surgery group and 95 percent in the SABR group, while recurrence-free survival rates at three years were 80 percent and 86 perc. The findings of our stud...